What is the evidence for PT-141 / Bremelanotide?
PT-141 is commonly marketed more broadly than the evidence allows. The decision-grade record concerns FDA-reviewed bremelanotide, its subcutaneous formulation, and one narrow population and indication.
DIRECT ANSWER
PT-141 / Bremelanotide evidence summary.
PT-141 is commonly marketed more broadly than the evidence allows. The decision-grade record concerns FDA-reviewed bremelanotide, its subcutaneous formulation, and one narrow population and indication.
Reviewed August 8, 2026. Each statement links to its evidence record, followed by the primary and official sources used for this answer.
Two randomized phase 3 trials support branded bremelanotide for acquired, generalized HSDD in premenopausal women.
Open evidence recordMechanism and nonclinical safety were evaluated as part of product development; the clinical conclusion remains indication-specific.
Open evidence recordAn approval for Vyleesi does not validate every product sold as PT-141 or use in populations outside the label.
Open evidence recordPRIMARY & OFFICIAL SOURCES
Sources for this answer.
3 source records, with duplicates removed.